Myriad Genetics (Nasdaq: MYGN) and SOPHiA GENETICS (Nasdaq: SOPH) announced a strategic collaboration on September 23, 2025, to develop and provide pharmaceutical companies with an innovative global liquid biopsy companion diagnostic (CDx) test. The partnership combines Myriad's advanced laboratory capabilities in the United States with SOPHiA GENETICS' extensive decentralized network of more than 800 connected institutions across more than 70 countries.
Strategic Focus on Liquid Biopsy Technology
The collaboration will initially center on MSK-ACCESS® powered with SOPHiA DDM™, an innovative liquid biopsy test developed in partnership with Memorial Sloan Kettering Cancer Center. This test detects actionable genomic alterations from a single blood draw using proprietary, state-of-the-art algorithms that analyze circulating tumor DNA (ctDNA).
"Serving patients and healthcare providers along the cancer care continuum is a strategic focus for Myriad Genetics," said Sam Raha, President and CEO of Myriad Genetics. "We expect this collaboration with SOPHiA GENETICS to support the development and global commercialization of comprehensive CDx solutions for our BioPharma partners with the potential to positively impact patient lives, add an important product offering to the Myriad menu and support the growth of our CDx programs."
Hybrid Regulatory Approach
The partnership employs an innovative hybrid regulatory strategy designed to maximize global market access. Myriad will pursue regulatory submissions in the United States, while SOPHiA GENETICS will manage regulatory submissions outside of the U.S. Both companies will collaborate across development activities, providing pharmaceutical partners with access to key regulated markets globally.
This approach is expected to expand patient access to high-quality tumor profiling tests while advancing personalized healthcare at scale. By developing the MSK-ACCESS® application into a companion diagnostic, the companies aim to make the benefits of this tumor profiling technology available to more patients worldwide.
Industry Impact and Technology Integration
"This collaboration represents a pivotal moment for the industry," said Jurgi Camblong, Co-founder and CEO of SOPHiA GENETICS. "By combining the complementary strengths of a specialty lab leader and a global testing network, we are not only expanding access to innovative oncology testing but also laying the foundation for a new hybrid model in companion diagnostics. This collaboration will allow us to serve both clinical and pharmaceutical partners better, while accelerating the adoption of liquid biopsy solutions across key markets."
The partnership leverages SOPHiA GENETICS' SOPHiA DDM™ Platform, which analyzes complex genomic and multimodal data and generates real-time, actionable insights for a broad global network of hospital, laboratory, and biopharma institutions. This cloud-native healthcare technology platform uses AI to deliver data-driven medicine for patients with cancer and rare disorders.
Market Positioning and Future Outlook
The collaboration positions both companies to better serve the growing demand for companion diagnostics in oncology. Myriad Genetics, a leader in molecular diagnostic testing and precision medicine, develops molecular tests that help assess disease risk and guide treatment decisions across medical specialties where molecular insights can significantly improve patient care and lower healthcare costs.
The companies plan to participate in a panel discussion at the World CB and CDx Summit in Boston, where they will provide additional details about their collaboration and its potential impact on the companion diagnostics landscape.
